Medical societies unify to endorse evidence-based respiratory vaccine guidance
Published . Updated .
Key takeaways
- Hoping to provide much-needed guidance to clinicians treating patients with lung disease and to promote respiratory health, the Vaccine Guidance Review Panel, a multi-medical society effort, announced its endorsement of influenza, RSV and COVID-19 recommendations for adults and
- Exposed: XLV, XBI, LLY, JNJ, PFE
- Market reaction: XBI −4.3% by the next session; XLV −2.5% by the next session; PFE −4.6% by the next session
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
Hoping to provide much-needed guidance to clinicians treating patients with lung disease and to promote respiratory health, the Vaccine Guidance Review Panel, a multi-medical society effort, announced its endorsement of influenza, RSV and COVID-19 recommendations for adults and
Directly affected
- No company is named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “vaccine” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “vaccine” (pharma and health) in this story.
- LLY Eli Lilly and+15.5% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “vaccine” (pharma and health) in this story.
- JNJ Johnson & Johnson+0.1% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “vaccine” (pharma and health) in this story.
- PFE Pfizer+4.0% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “vaccine” (pharma and health) in this story.
- MRK Merck+3.5% 30d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “vaccine” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| XLV | -2.96% | -2.66% | base | -2.36% | -2.53% | after close | after close |
| XBI | -0.81% | -4.43% | base | -6.73% | -4.33% | after close | after close |
| LLY | -3.15% | -0.45% | base | -3.07% | -4.46% | after close | after close |
| JNJ | -0.43% | -2.09% | base | -1.43% | -0.00% | after close | after close |
| PFE | -2.73% | -0.26% | base | -2.96% | -4.56% | after close | after close |
| MRK | -2.69% | -1.28% | base | -2.02% | -2.40% | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Medical societies unify to endorse evidence-based respiratory vaccine guidance News-Medical
Source: News-Medical
Select Sector Spdr Tr (XLV)
Across 4 earlier stories, Select Sector Spdr Tr (XLV) the next day averaged -2.53%. The largest gain was -2.53% and the largest drop was -2.53%, from 4 prices.
| Company | When | Average | Largest gain | Largest drop | Prices |
|---|---|---|---|---|---|
| Select Sector Spdr Tr (XLV) | the next day | -2.53% | -2.53% | -2.53% | 4 |
| Spdr Series Trust (XBI) | the next day | -4.33% | -4.33% | -4.33% | 4 |
| Eli Lilly (LLY) | the next day | -4.46% | -4.46% | -4.46% | 4 |
| Johnson & Johnson (JNJ) | the next day | 0.00% | -0.00% | -0.00% | 4 |
How far Select Sector Spdr Tr (XLV) has moved since 5 Nov 2026
| Company | When | Move | Status |
|---|---|---|---|
| Johnson & Johnson (JNJ) | that day | -1.43% | final price |
| Johnson & Johnson (JNJ) | the next day | -0.00% | final price |
| Johnson & Johnson (JNJ) | three days earlier | -2.09% | final price |
| Johnson & Johnson (JNJ) | five days earlier | -0.43% | final price |
| Eli Lilly (LLY) | that day | -3.07% | final price |
| Eli Lilly (LLY) | the next day | -4.46% | final price |
| Eli Lilly (LLY) | three days earlier | -0.45% | final price |
| Eli Lilly (LLY) | five days earlier | -3.15% | final price |
| Merck (MRK) | that day | -2.02% | final price |
| Merck (MRK) | the next day | -2.40% | final price |
| Merck (MRK) | three days earlier | -1.28% | final price |
| Merck (MRK) | five days earlier | -2.69% | final price |
| Pfizer (PFE) | that day | -2.96% | final price |
| Pfizer (PFE) | the next day | -4.56% | final price |
| Pfizer (PFE) | three days earlier | -0.26% | final price |
| Pfizer (PFE) | five days earlier | -2.73% | final price |
| Spdr Series Trust (XBI) | that day | -6.73% | final price |
| Spdr Series Trust (XBI) | the next day | -4.33% | final price |
| Spdr Series Trust (XBI) | three days earlier | -4.43% | final price |
| Spdr Series Trust (XBI) | five days earlier | -0.81% | final price |
| Select Sector Spdr Tr (XLV) | that day | -2.36% | final price |
| Select Sector Spdr Tr (XLV) | the next day | -2.53% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | -2.66% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | -2.96% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 62 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 36 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 41 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 58 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 62 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 76 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 42 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 78 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLV)
Companies mentioned with this story
- XLV Select Sector Spdr Tr
Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence in the 5 Nov 2026 story “Medical societies unify to endorse evidence-based respiratory vaccine guidance.” Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “vaccine” (pharma and health) in this story
- XBI Spdr Series Trust
Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence in the 5 Nov 2026 story “Medical societies unify to endorse evidence-based respiratory vaccine guidance.” Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “vaccine” (pharma and health) in this story
- LLY Eli Lilly
For “Medical societies unify to endorse evidence-based respiratory vaccine guidance,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “vaccine” (pharma and health) in this story
- JNJ Johnson & Johnson
In “Medical societies unify to endorse evidence-based respiratory vaccine guidance,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “vaccine” (pharma and health) in this story
- PFE Pfizer
In “Medical societies unify to endorse evidence-based respiratory vaccine guidance,” Pfizer (PFE) is linked, with no stored direction, medium confidence. Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “vaccine” (pharma and health) in this story
- MRK Merck
For “Medical societies unify to endorse evidence-based respiratory vaccine guidance,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “vaccine” (pharma and health) in this story
Select Sector Spdr Tr (XLV)
The 5 Nov 2026 story “Medical societies unify to endorse evidence-based respiratory vaccine guidance” names Select Sector Spdr Tr (XLV) because of this story.
For Select Sector Spdr Tr (XLV), the reason on file says Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “vaccine” (pharma and health) in this story
A second company, Spdr Series Trust (XBI), is listed for a different reason: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “vaccine” (pharma and health) in this story
Dates in the story, and the Select Sector Spdr Tr (XLV) price range
LLY traded between 1151.01 and 1452.66 across 20 sessions. The latest close on file is 1367.27.
What the saved facts support for Select Sector Spdr Tr (XLV)
46 out of 100
“Medical societies unify to endorse evidence-based respiratory vaccine guidance” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.